| http://www.w3.org/ns/prov#value | - iance through directly observed therapy in the presence of a physician.Pfizer claimed that the anti-schizophrenia drug, Geodon, had grown in market share and in new and total prescriptions, suggesting the market had become receptive to its benefits, including efficacy, dosing flexibility and favourable metabolic and weight-gain profile compared to older anti-psychotic agents.Another newly launched
|
